Flu surge boosts demand for medications and diagnostics in South Korea Flu season drives sharp rise in pharmaceutical sales ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Eli Lilly has opted to end a phase 2 rheumatoid arthritis (RA) trial of a drug it is developing with Korea’s Hanmi Pharmaceuticals, according to press reports. The Korea Biomedical Review cited ...

The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea's Hanmi Pharma, which originally ...

APS), a clinical-stage precision oncology company developing highl Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed ...

the expansion of pharmaceutical companies into developing regions, and growing acceptance of injectable therapies. The semaglutides market size is expected to see rapid growth in the next few years.

The growth during the historic period can be attributed to lifestyle changes leading to higher diabetes prevalence, increased investment in research and development, rising healthcare expenditure, the ...